Premium
Photoallergic contact dermatitis from topical diclofenac in Solaraze ® gel
Author(s) -
Kowalzick L.,
Ziegler H.
Publication year - 2006
Publication title -
contact dermatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.524
H-Index - 96
eISSN - 1600-0536
pISSN - 0105-1873
DOI - 10.1111/j.0105-1873.2006.0645f.x
Subject(s) - dermatology , diclofenac , medicine , contact dermatitis , rash , erythema , irritant contact dermatitis , dry skin , allergy , pharmacology , immunology
Solaraze ® gel (Shire Deutschland GmbH & Co. KG, Cologne, Germany) containing 3% diclofenac has been licensed in 2001 as a topical treatment for actinic keratoses. It is commonly used in dermatological practice. Undesirable effects are believed to be rare but include pruritus, paresthesia and application‐site reactions (dry skin, rash, erythema, contact dermatitis and vesicobullous eruptions). Recently, a few cases of contact dermatitis due to three different allergens including diclofenac have been reported (1,2).